Clinical Trial

Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)

Study acronym: STRENGTH
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.
Trial Details
NCT Number NCT07489911
Lead Sponsor Chiesi Slovenija, d.o.o.
Conditions Asthma, Asthma Patients, Asthma Bronchiale
Enrollment 200 participants
Start Date 2024-11-04
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-24